Evidence map›Paper›PMID 40772934›Full record

Trial reportMicrobiology spectrum2025

Marta Perez, Eva Armengol, Antonio Del Casale, Ilenia Campedelli, Ana Aldea-Perona, Marta Pérez Otero, Maria Rodriguez-Palmero, Jordi Espadaler-Mazo, Pol Huedo

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Orally ingestedFrontiers in microbiology · 2026
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marta Perez *R&D Department, AB-Biotics S.A. (Part of Kaneka Corporation), Barcelona, Spain.ORCID 0000-0002-1059-3677
Eva Armengol *R&D Department, AB-Biotics S.A. (Part of Kaneka Corporation), Barcelona, Spain.
Antonio Del CasaleOpen Innovation Department, MICROBION srl, Verona, Italy.
Ilenia CampedelliOpen Innovation Department, MICROBION srl, Verona, Italy.
Ana Aldea-PeronaClinical Pharmacology, Hospital del Mar, Barcelona, Spain.
Marta Pérez OteroClinical Pharmacology, Hospital del Mar, Barcelona, Spain.
Maria Rodriguez-PalmeroR&D Department, AB-Biotics S.A. (Part of Kaneka Corporation), Barcelona, Spain.
Jordi Espadaler-MazoR&D Department, AB-Biotics S.A. (Part of Kaneka Corporation), Barcelona, Spain.
Pol HuedoR&D Department, AB-Biotics S.A. (Part of Kaneka Corporation), Barcelona, Spain.ORCID 0000-0002-2933-0586

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaginal dysbiosis is linked to recurrent infections and reproductive complications. Probiotics may restore vaginal microbiota, but there is modest evidence to support vaginal colonization after oral administration. This work aimed to screen a vaginal lactobacilli collection (

Indexed as

Lactobacillus gasseriProbioticsVaginaAdministration, OralAdolescentAdultDysbiosisFemaleHealthy VolunteersHumansLactobacillus crispatusMicrobiotaMiddle AgedYoung Adultantagonism activityclinical studydysbiosisvaginal colonizationvaginal lactobacilli

Identifiers

PMID40772934
PMCPMC12403894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.